Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04146129 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of CDX-0159

A Phase 1 study of Healthy Subjects, sponsored by Celldex Therapeutics.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT04146129 is a Phase 1 study of Healthy Subjects that has completed, run by Celldex Therapeutics. The registered enrollment target is 32 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04146129, a Phase 1 study of Healthy Subjects, has completed, sponsored by Celldex Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This is a study to determine the safety of CDX-0159 in healthy subjects.

Conditions Studied

Interventions

  • DRUG Normal saline
  • DRUG CDX-0159

Study Locations (1)

Kansas

  • Altasciences Clinical Kansas, Inc. - Overland Park

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2019-10-29
Est. Completion 2020-06-26
Phase Phase 1

Sponsor

Celldex Therapeutics

42 total trials

What the Registry Record Tells You About NCT04146129

The ClinicalTrials.gov registry entry for NCT04146129 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (75% lower). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.

NCT04146129 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT04146129 about?

NCT04146129 is a clinical study titled "A Phase 1 Study of CDX-0159". This is a study to determine the safety of CDX-0159 in healthy subjects.

What is the current status of trial NCT04146129?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-10-29. Estimated completion is 2020-06-26.

What conditions does trial NCT04146129 study?

This clinical trial studies the following conditions: Healthy Subjects.

What interventions are being tested in trial NCT04146129?

The interventions under investigation include: Normal saline (DRUG), CDX-0159 (DRUG).

Who is sponsoring clinical trial NCT04146129?

This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04146129 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Subjects

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.